Data on Parkinson's disease therapy CVT-301 published in Science Translational Medicine
CVT-301, an inhaled form of levodopa, is being studied for its potential to restore motor function in people with Parkinson's disease experiencing OFF periods. The Phase 3 clinical program aims to confirm the efficacy and safety profile of CVT-301.